Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

The Cardiac Centre at Al Qassimi Hospital, operated by Emirates Health Services (EHS), has become the first facility in the ...

Hypertension affects 1 in 3 adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Other causes of PAA include pulmonary hypertension, vasculitis, syphilis, tuberculosis, left-to-right shunts, pulmonary valve stenosis with post-stenotic dilatation, vasa vasorum dysfunction, trauma, ...

Context Knowledge gaps exist on the incidence and risk factors for developing pulmonary hypertension (PH) in preterm infants with bronchopulmonary dysplasia (BPD) and its impact on outcomes. Objective ...

Another potential presentation of unrepaired PDA is Eisenmenger syndrome (ES), though rare in children, 7 which results in severe pulmonary hypertension. 8 As described earlier, a hemodynamically ...